Legal Advantage Investments Inc. Sells 400 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Legal Advantage Investments Inc. trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.2% during the 4th quarter, Holdings Channel reports. The fund owned 9,160 shares of the medical equipment provider’s stock after selling 400 shares during the period. Legal Advantage Investments Inc.’s holdings in Zimmer Biomet were worth $968,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZBH. Dunhill Financial LLC grew its holdings in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $28,000. Bangor Savings Bank bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $31,000. Brooklyn Investment Group bought a new stake in shares of Zimmer Biomet in the 3rd quarter valued at about $35,000. Finally, Quarry LP bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at about $53,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ZBH. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Oppenheimer decreased their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Raymond James decreased their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Finally, Wells Fargo & Company increased their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Stock Up 0.7 %

NYSE ZBH opened at $109.65 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $100.67 and a 52 week high of $133.90. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The business’s fifty day simple moving average is $107.84 and its 200-day simple moving average is $108.02. The firm has a market cap of $21.83 billion, a PE ratio of 20.85, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.65 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.